Bruton's Tyrosine Kinase (BTK) Inhibitors Plus RM (rituximab and methotrexate) for the First-Line Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Authors

+5 authors

Journal

Published

Nov 5, 2024

DOI

Save

Tip

Document

Download

Flag content

Tip

Save

Document

Download

Flag content

Abstract

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.